Drug intelligence / Profile preview

YL-0336

Development stage: Preclinical
Lead developer: Ionova Life Science
Modality: Small Molecules

Overview

YL-0336 is an investigational small molecule inhibitor of signal transducer and activator of transcription 6 (STAT6) being developed by Ionova Life Science. STAT6 is a critical transcription factor in the JAK/STAT signaling pathway that is activated by interleukins IL-4 and IL-13, playing a central role in driving Th2 cell differentiation and type 2 inflammatory responses. By selectively inhibiting STAT6, YL-0336 aims to suppress pathological immune activation and downstream inflammatory cascades. The therapeutic candidate is currently in preclinical development for the treatment of autoimmune diseases.

Targets

STAT6 (Signal Transducer and Activator of Transcription 6)

Beyond the preview

Go deeper on YL-0336.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on YL-0336.

Explore the full profile